Jun 2021 $4 M No. 6 $2 to $10 million 38
Triangle Therapeutics Inc.: Raise no. 6, Jun 2021 × Investors in this round 38 investors had bought by the notice of May 17, 2022: 38 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carl W. McKinzie · Executive Officer, Director Jean B. deKernion · Executive Officer, Director Kenneth A. Schultz, M.D. · Executive Officer, Director Louis L. Gonda · Director Timothy B. Donahue, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kenneth A. Schultz, M.D., Ceo. Source: SEC Form D, newest notice filed May 17, 2022. Read the notice at the SEC .
equity, options SEC Feb 2020 $3 M No. 5 $2 to $10 million 25
Triangle Therapeutics Inc.: Raise no. 5, Feb 2020 × Investors in this round 25 investors had bought by the notice of Feb 24, 2021: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carl W. McKinzie · Executive Officer, Director Jean B. deKernion · Executive Officer, Director Kenneth A. Schultz, M.D. · Executive Officer, Director Louis L. Gonda · Director Timothy L. Donahue, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kenneth A. Schultz, M.D., Ceo. Source: SEC Form D, newest notice filed Feb 24, 2021. Read the notice at the SEC .
equity, options SEC Mar 2019 $8 M No. 4 $2 to $10 million 28
Triangle Therapeutics Inc.: Raise no. 4, Mar 2019 × Investors in this round 28 investors had bought by the notice of Mar 11, 2019: 28 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carl W. McKinzie · Executive Officer, Director Jean B. deKernion · Executive Officer, Director Kenneth A. Schultz, M.D. · Executive Officer, Director Lynne W. Rollins · Executive Officer Louis L. Gonda · Director Timothy L. Donahue, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Lynne Rollins, Cfo. Source: SEC Form D, newest notice filed Mar 11, 2019. Read the notice at the SEC .
equity, options SEC Feb 2017 $4 M No. 3 $2 to $10 million 19
Triangle Therapeutics Inc.: Raise no. 3, Feb 2017 × Investors in this round 19 investors had bought by the notice of Mar 7, 2017: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $5 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carl W. McKinzie · Executive Officer, Director Johanna Holldack · Executive Officer, Director Lynne W. Rollins · Executive Officer Nathan W. Mata · Executive Officer Jean B. deKernion · Director Louis L. Gonda · Director Owen L. Witte, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “This amount includes convertible promissory notes, warrants to purchase preferred stock, the preferred stock issuable upon exercise of the warrants and common stock issuable upon conversion thereof.”Signed by Lynne Rollins, Cfo. Source: SEC Form D, newest notice filed Mar 7, 2017. Read the notice at the SEC .
equity, options SEC Feb 2016 $10 M No. 2 $10 to $50 million 43
Triangle Therapeutics Inc.: Raise no. 2, Feb 2016 × Investors in this round 43 investors had bought by the notice of Oct 20, 2016: 43 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $20 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carl W. McKinzie · Executive Officer, Director Johanna Holldack · Executive Officer, Director Lynne W. Rollins · Executive Officer Nathan W. Mata · Executive Officer Caius B. Radu · Director Jean B. deKernion · Director Johannes Czernin · Director Louis L. Gonda · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “This amount includes preferred stock, common stock, warrants and common stock issuable upon conversion of preferred stock/exercise of warrants.”Signed by Johanna Holldack, M.D., President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Oct 20, 2016. Read the notice at the SEC .
equity, options SEC Apr 2015 $5 M No. 1 $2 to $10 million 26
Triangle Therapeutics Inc.: Raise no. 1, Apr 2015 × Investors in this round 26 investors had bought by the notice of Jul 2, 2015: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $6 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Carl McKinzie · Executive Officer, Director Caius L. Radu · Director Jean L. deKernion · Director Johannes L. Czernin · Director Louis L. Gonda · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Estimated”Signed by Carl McKinzie, President. Source: SEC Form D, newest notice filed Jul 2, 2015. Read the notice at the SEC .
equity, debt, options SEC